BFRI | tickerfilter.com

Fundamental analysis

54%

Profitability 35%

Dept financing 40%

Liquidity 67%

Performance 74%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.92%

1 Month

33.37%

3 Months

8.22%

6 Months

5.37%

1 Year

28.72%

2 Year

-32.08%

Key data

Stock price

$1.08

P/E Ratio

N/A

DAY RANGE

$1.02 - $1.12

EPS

-$0.72

52 WEEK RANGE

$0.54 - $1.19

52 WEEK CHANGE

$28.72

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

11.648 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

-0.64

PUBLIC FLOAT

AVERAGE 10 VOLUME

$133,552

AVERAGE 30 VOLUME

$127,821

Company detail

CEO: Erica L. Monaco
Region: US
Website: biofrontera.us.com
Employees: 70
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Biofrontera Inc. engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device. The RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

BFRI - Biofrontera Inc.